Risk factors associated with bleeding after alteplase administration for pulmonary embolism: A case-control study

Pharmacotherapy

Volumn 34, Issue 8, 2014, Pages 818-825

  Curtis, Garrett M ^a   Lam, Simon W ^b   Reddy, Anita J ^b   Bauer, Seth R ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

bleeding; pulmonary embolism; risk factors; thrombolytic therapy

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; BLEEDING; BODY WEIGHT; CASE CONTROL STUDY; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG SAFETY; FEMALE; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; INTERNATIONAL NORMALIZED RATIO; LENGTH OF STAY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MAJOR SURGERY; MALE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; CHEMICALLY INDUCED; HEMORRHAGE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PULMONARY EMBOLISM; RETROSPECTIVE STUDY; RISK; STATISTICAL MODEL;

ADULT; AGED; CASE-CONTROL STUDIES; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PULMONARY EMBOLISM; RETROSPECTIVE STUDIES; RISK FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84905920305     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1440     Document Type: Conference Paper

References (27)

1. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 2013; 127: e6-245.
2. Konstantinides S,. Clinical practice. Acute pulmonary embolism. N Engl J Med 2008; 359: 2804-13.
3. Wan S, Quinlan DJ, Agnelli G, Eikelboom JW,. Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. Circulation 2004; 110: 744-9.
4. Dong BR, Hao Q, Yue J, Wu T, Liu GJ,. Thrombolytic therapy for pulmonary embolism. Cochrane Database Syst Rev 2009; 3: CD004437.
5. Jaff MR, McMurtry MS, Archer SL, et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. Circulation 2011; 123: 1788-830.
6. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e419S-94S.
7. Goldhaber SZ, Visani L, De Rosa M,. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999; 353: 1386-9.
8. Genentech Inc Activase [package insert]. South San Francisco, CA; 2011.
9. Schulman S, Kearon C,. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 692-4.
10. Todd JL, Tapson VF,. Thrombolytic therapy for acute pulmonary embolism: a critical appraisal. Chest 2009; 135: 1321-9.
11. Landefeld CS, McGuire E 3rd, Rosenblatt MW,. A bleeding risk index for estimating the probability of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med 1990; 89: 569-78.
12. Mehta RH, Stebbins A, Lopes RD, et al. Race, bleeding, and outcomes in STEMI patients treated with fibrinolytic therapy. Am J Med 2011; 124: 48-57.
13. Goldhaber SZ,. Thrombolytic therapy for patients with pulmonary embolism who are hemodynamically stable but have right ventricular dysfunction: pro. Arch Intern Med 2005; 165: 2197-9; discussion 204-5.
14. Agnelli G, Becattini C, Kirschstein T,. Thrombolysis vs heparin in the treatment of pulmonary embolism: a clinical outcome-based meta-analysis. Arch Intern Med 2002; 162: 2537-41.
15. Fiumara K, Kucher N, Fanikos J, Goldhaber SZ,. Predictors of major hemorrhage following fibrinolysis for acute pulmonary embolism. Am J Cardiol 2006; 97: 127-9.
16. Kanter DS, Mikkola KM, Patel SR, Parker JA, Goldhaber SZ,. Thrombolytic therapy for pulmonary embolism. Frequency of intracranial hemorrhage and associated risk factors. Chest 1997; 111: 1241-5.
17. Meyer G, Gisselbrecht M, Diehl JL, Journois D, Sors H,. Incidence and predictors of major hemorrhagic complications from thrombolytic therapy in patients with massive pulmonary embolism. Am J Med 1998; 105: 472-7.
18. Mikkola KM, Patel SR, Parker JA, Grodstein F, Goldhaber SZ,. Increasing age is a major risk factor for hemorrhagic complications after pulmonary embolism thrombolysis. Am Heart J 1997; 134: 69-72.
19. Stein PD, Hull RD, Raskob G,. Risks for major bleeding from thrombolytic therapy in patients with acute pulmonary embolism. Consideration of noninvasive management. Ann Intern Med 1994; 121: 313-7.
20. Brass LM, Lichtman JH, Wang Y, Gurwitz JH, Radford MJ, Krumholz HM,. Intracranial hemorrhage associated with thrombolytic therapy for elderly patients with acute myocardial infarction: results from the Cooperative Cardiovascular Project. Stroke 2000; 31: 1802-11.
21. Wang C, Zhai Z, Yang Y, et al. Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism: a randomized, multicenter, controlled trial. Chest 2010; 137: 254-62.
22. Goldhaber SZ, Feldstein ML, Sors H,. Two trials of reduced bolus alteplase in the treatment of pulmonary embolism. An overview. Chest 1994; 106: 725-6.
23. Levine M, Hirsh J, Weitz J, et al. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest 1990; 98: 1473-9.
24. Sharifi M, Bay C, Skrocki L, Rahimi F, Mehdipour M,. Moderate pulmonary embolism treated with thrombolysis (from the "MOPETT" Trial). Am J Cardiol 2013; 111: 273-7.
25. Capstick T, Henry MT,. Efficacy of thrombolytic agents in the treatment of pulmonary embolism. Eur Respir J 2005; 26: 864-74.
26. Daley MJ, Lat I,. Clinical controversies in thrombolytic therapy for the management of acute pulmonary embolism. Pharmacotherapy 2012; 32: 158-72.
27. Meyer G, Vicaut E, Danays T, et al. Fibrinolysis for patients with Intermediate-Risk Pulmonary Embolism. N Engl J Med 2014; 370: 1402-11.